|
New hope for regenerative medicine
February 15, 2007Hematopoietic reconstitution with uniparental stem cells
In the February 15th issue of G&D, Dr. K. John McLaughlin and colleagues report on their success in using uniparental embryonic stem cells to replace blood stem cells in mice. Uniparental embryonic stem cells are an appealing alternative source of patient-derived embryonic stem cells, as they have several advantages over embryonic stem cell lines generated by somatic cell nuclear transfer (also known as therapeutic cloning).
Normal mammalian embryos inherit one set of chromosomes from the mother, and one set from the father. Embryos that inherit both sets of chromosomes from the same parent are not viable. They can, however, generate "uniparental" embryonic stem cell lines. Uniparental embryos with two maternal sets of chromosomes are known as parthenogenetic. These embryos have been considered a potential source of embryonic stem cell derived tissues for transplantation into the female from which they were derived.
This study shows for the first time that parthenogenetic blood cells can replace those of an immunocompromised adult mouse. McLaughlin and colleagues also show that this is also possible using embryonic stem cells where both genomes are solely derived from sperm of one male (androgenetic), adding fertile males to the potential patient pool.
Since uniparental ES cells are not derived from viable embryos, their harvesting and use sidesteps many of the ethical concerns that plague traditional ES cell therapies. However, uniparental ES cell research faces the biological hurdle of genomic imprinting, in which specific gene expression patterns are dictated by the parental origin. Uniparental cells only have the imprinting marks for one parental type (or "from one parent") with unknown consequences if harvested and transplanted into adults.
Previous work has shown that uniparental ES cells have only limited ability to contribute to fetal and postnatal development in chimeric animals, with androgenetically-derived uniparental ES cell chimeras displaying abnormal phenotypes and increased lethality. In their current paper, Dr. McLaughlin and colleagues tested the functionality of uniparental ES cells in adult tissues.
"It has been known for over a decade that uniparental cells had some capacity to form tissues in vitro and in vivo but it was questionable if these embryonic stem cells could generate transplantable material that would proliferate and replace tissues in an adult."
The researchers took a two-step approach: First they injected uniparental ES cells into wild-type blastocyts to generate chimeric animals; then they harvested these chimeric fetal livers for transplant into lethally irradiated hosts. The scientists found that uniparental ES cells, regardless of parent-of-origin, were able to functionally reconstitute the entire hematopoietic system of adult mice. Furthermore, the scientists were also able to grow progenitor blood cells in culture from uniparental ES cells, and upon transplant into irradiated adult mice, show that these cells contribute, long-term, to the function of their hematopoietic system.
One issue in using uniparental ES cells for tissue transplants is their durability and safety. McLaughlin's group were able to maintain animals for over 12 months with entirely uniparental blood and were able to rescue irradiated mice with bone marrow transplants from these animals. This unambiguously proves that the transplanted uniparental cells could produce hematopoietic stem cells.
"The ability of the "sperm derived" androgenetic cells to replace adult blood was totally unexpected based on what occurs with these cells during development. The male derived androgenetic cells were at least as effective as the maternal derived cells."
Dr. McLaughlin's new paper expands the horizons for regenerative medicine, not only by demonstrating that uniparental stem cells can form adult-transplantable progenitor cells in cell culture, but also by illustrating the potential utility of androgenetic, as well as parthenogenetic ES cells.
Cold Spring Harbor Laboratory
This study shows for the first time that parthenogenetic blood cells can replace those of an immunocompromised adult mouse. McLaughlin and colleagues also show that this is also possible using embryonic stem cells where both genomes are solely derived from sperm of one male (androgenetic), adding fertile males to the potential patient pool.
Since uniparental ES cells are not derived from viable embryos, their harvesting and use sidesteps many of the ethical concerns that plague traditional ES cell therapies. However, uniparental ES cell research faces the biological hurdle of genomic imprinting, in which specific gene expression patterns are dictated by the parental origin. Uniparental cells only have the imprinting marks for one parental type (or "from one parent") with unknown consequences if harvested and transplanted into adults.
Previous work has shown that uniparental ES cells have only limited ability to contribute to fetal and postnatal development in chimeric animals, with androgenetically-derived uniparental ES cell chimeras displaying abnormal phenotypes and increased lethality. In their current paper, Dr. McLaughlin and colleagues tested the functionality of uniparental ES cells in adult tissues.
"It has been known for over a decade that uniparental cells had some capacity to form tissues in vitro and in vivo but it was questionable if these embryonic stem cells could generate transplantable material that would proliferate and replace tissues in an adult."
The researchers took a two-step approach: First they injected uniparental ES cells into wild-type blastocyts to generate chimeric animals; then they harvested these chimeric fetal livers for transplant into lethally irradiated hosts. The scientists found that uniparental ES cells, regardless of parent-of-origin, were able to functionally reconstitute the entire hematopoietic system of adult mice. Furthermore, the scientists were also able to grow progenitor blood cells in culture from uniparental ES cells, and upon transplant into irradiated adult mice, show that these cells contribute, long-term, to the function of their hematopoietic system.
One issue in using uniparental ES cells for tissue transplants is their durability and safety. McLaughlin's group were able to maintain animals for over 12 months with entirely uniparental blood and were able to rescue irradiated mice with bone marrow transplants from these animals. This unambiguously proves that the transplanted uniparental cells could produce hematopoietic stem cells.
"The ability of the "sperm derived" androgenetic cells to replace adult blood was totally unexpected based on what occurs with these cells during development. The male derived androgenetic cells were at least as effective as the maternal derived cells."
Dr. McLaughlin's new paper expands the horizons for regenerative medicine, not only by demonstrating that uniparental stem cells can form adult-transplantable progenitor cells in cell culture, but also by illustrating the potential utility of androgenetic, as well as parthenogenetic ES cells.
Cold Spring Harbor Laboratory
Regenerative Medicine News and Current Regenerative Medicine Events RSSPenn researchers find key developmental pathway activates lung stem cells
Researchers from the University of Pennsylvania School of Medicine found that the activation of a molecular pathway important in stem cell and developmental biology leads to an increase in lung stem cells. Harnessing this knowledge could help develop therapies for lung-tissue repair after injury or disease.
Wealth of genomic hotspots discovered in embryonic stem cells
In a paper published in Cell on June 13, 2008, Singapore scientists at the Genome Institute of Singapore (GIS) and the National University of Singapore (NUS) unveil an atlas that showing the location of "genomic hotspots" of essential protein "switches" (transcription factors) that are critical for maintaining the embryonic stem (ES) cell state.
UCLA researchers identify leukemia stem cells
Stem cell researchers at UCLA have identified a type of leukemia stem cell and uncovered the molecular and genetic mechanisms that cause a normal blood stem cells to become cancerous.
USC stem cell study sheds new light on cell mechanism
Research from the University of Southern California (USC) has discovered a new mechanism to allow embryonic stem cells to divide indefinitely and remain undifferentiated.
UCLA stem cell researchers create heart and blood cells from reprogrammed skin cells
Stem cell researchers at UCLA were able to grow functioning cardiac cells using mouse skin cells that had been reprogrammed into cells with the same unlimited properties as embryonic stem cells.
Menstrual blood -- a valuable source of multipotential stem cells?
Researchers seeking new and more abundant sources of stem cells for use in regenerative medicine have identified a potentially unlimited, noncontroversial, easily collectable, and inexpensive source - menstrual blood.
Chemotherapy causes delayed severe neural damage
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
Rice and UT-Houston join DOD push for regenerative medicine
The Department of Defense (DOD) today announced that Rice University and the University of Texas Health Science Center at Houston will spearhead the search for innovative ways to quickly grow large volumes of bone tissue for craniofacial reconstruction for soldiers wounded in Iraq and Afghanistan.
Embryonic stem cells could help to overcome immune rejection problems
Tissues derived from embryonic stem (ES) cells could help to pacify the immune system and so prevent recipients from rejecting them, the UK National Stem Cell Network Science Meeting will hear today (11 April).
Method to deliver molecules within embryonic stem cells improves differentiation
Embryonic stem cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease. However, the inability of stem cells to efficiently develop into the desired specific cell type - such as muscle, skin, blood vessels, bone or neurons - now limits the potential clinical utility of this therapy.
More Regenerative Medicine News Articles
| © 2008 BrightSurf.com |